Evaluating Serplulimab with Chemotherapy for Lung Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial aims to assess the efficacy and safety of Serplulimab combined with chemotherapy as a conversion treatment for patients with stage IIIB-IVA oligometastatic non-small cell lung cancer (NSCLC). The study is single-arm and open-label, focusing on the rate of NSCLC converting to resectable tumors and the one-year progression-free survival rate as primary endpoints. Secondary endpoints include rates of R0 resection, major pathological response, overall survival, and progression-free survival, alongside multi-omics analysis to identify potential biomarkers for treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients should voluntarily join this study and sign the informed consent form
2. NSCLC patients diagnosed by cytology or histology and not previously receiving anti-tumor treatments (including systemic treatments, local treatments .etc)
3. Patients with IIIB - IVA oligometastatic NSCLC : (a) IIIB - IIIC stage (T1-4N2-3): patients are not suitable or refuse to receive upfront surgical resection or radiotherapy; (b) oligometastatic stage IV (T1-3N0-2): radical resection/radiotherapy is feasible for metastatic lesions (the number of metastases being up to 3, and the maximum diameter of metastases being up to 2cm)
4. After evaluation by MDT, upfront surgical resection is not the preferred treatment, but after induction systemic treatments, radical resection of the primary tumor is feasible, and radical resection/radiotherapy is feasible for extrathoracic metastases (if any)
5. Age from 18 to 75 years old, both male and female
6. ECOG score 0-1
7. According to the RECIST v1.1 , patients should have at least one measurable lesion
8. For suspicious mediastinal lymph nodes (including pathological enlargement or PET-CT indicating malignancy, etc.), further sampling is required for pathological diagnosis by EUBS, thoracoscopy, or mediastinoscopy
9. According clinical evaluation, the lung function of patients (such as FVC, FEV1, TLC, FRC, DLco, etc.) should be sufficient for pneumonectomy
10. The function of important organs should meet the following requirements: absolute count of neutrophils ≥ 1.5 × 109/L； Platelets ≥ 100 × 109/L； Hemoglobin ≥ 90g/L; Serum albumin ≥ 35g/L; Thyroid hormone (TSH) ≤ 1 × ULN； Serum bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 3 × ULN； International standardized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN； Serum creatinine ≤ 1.5 × ULN
11. Female patients at childbearing age are required to use contraceptive measures; for male patients whose partners are women at childbearing age, effective methods of contraception should be used during the trial period

Exclusion Criteria:

Patients who meet any of the following conditions will not be enrolled in this study:

1. NSCLC patients have sensitive EGFR mutation, EML4-ALK fusion or other forms of ALK gene changes
2. Patients have previously received immune checkpoint inhibitors such as PD-1/ PD-L1/CTLA4 antibody
3. Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)
4. Patients with active hepatitis B/C
5. Patients with any active autoimmune diseases or a history of autoimmune diseases
6. Patients who are using immunosuppressive agents or require systemic hormone therapy
7. Patients with hypertension but without good control even through antihypertensive medication treatment ; patients with clinical symptoms or diseases related to unsatisfying cardiac function
8. Patients with abnormal coagulation function (INR\>2.0, PT\>16s)
9. Arterial/venous thrombotic events occurred before screening within 6 months
10. Patients with active infection
11. Patients with congenital or acquired immune dysfunction (such as HIV infection)
12. According to the judgment of the researchers, patients have other factors that may affect the results of the research or cause the research to be terminated

Where it's running

• Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Weijia Fang, MD — First Affiliated Hospital of Zhejiang University
• Study coordinator: Peng Zhao, MD
• Email: zhaop@zju.edu.cn
• Phone: +86-18767186629

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• Understand cancer cachexia subtypes in advanced cancers

  This study tests how cancer cachexia presents in people with advanced colorectal, pancreatic, or lung cancer to see if different subtypes relate to outcomes.

  Recruiting Kaiser Permanente · Pleasanton, California · NCT07776353

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Low-dose carboplatin with nab-paclitaxel plus delayed serplulimab as first-line therapy for advanced squamous NSCLC

  This trial tests whether giving a low-dose carboplatin and nab-paclitaxel together, with serplulimab started after a delay, helps people with advanced squamous non-small cell lung cancer who have no known targetable gene mutations.

  Recruiting Phase 2 People's Hospital of Quzhou · Quzhou, Zhejiang · NCT07647094

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.